• ≥18 years and \<85 years old.

• Able to understand and provide a signed informed consent that fulfills the relevant Institutional Review Board (IRB) or Independent Ethics Committee (IEC) guidelines.

• Participants must be appropriate for single-agent therapy as the next line of therapy, as determined by the Investigator.

• Participants must have received prior treatment with bevacizumab.

• Confirmed diagnosis of platinum-resistant high-grade epithelial ovarian cancer, primary peritoneal or fallopian tube. Platinum-resistant is defined as a relapse within 6 months of receiving 1 to 3 platinum-based chemotherapy regimens.

• Must have at least one lesion that meets the definition of measurable disease defined by RECIST v1.1 criteria.

• Must have received at least one but no more than three prior systemic lines of anticancer therapy and had progressive disease (PD) while receiving or immediately after receiving the previous therapy. Progression will be calculated from the date of the last administered dose of platinum based therapy to the date of radiographic imaging that showed evidence of progression.

‣ Participants who had received one line of platinum-based therapy must have received at least four cycles of their initial platinum-containing regimen, had a response (complete or partial), and then had PD between 3 and 6 months after their last dose.

⁃ Participants who had previously received two or three lines of platinum-based therapy must have had PD while receiving the therapy or within 6 months after the last dose.

• Participants with germline or somatic BRCA1 or BRCA2 mutations must have received prior PARP inhibitor therapy as maintenance or treatment.

• Must have adequate peripheral venous access on both arms, or be willing to have temporary vascular access placed for apheresis collection, if deemed necessary by the Investigator.

⁃ Must be able to sit or recline with limited movement for approximately 6 hours during apheresis procedure.

⁃ Participants must have been previously tested for FRα. If the test result was positive, they must have been offered treatment with mirvetuximab soravtansine-gynx.

⁃ Agreement to practice effective contraception for female participants of childbearing potential. Female participants of childbearing potential must agree to use effective contraception for up to 7 months after completion of study treatment. Effective contraception includes surgical sterilization (eg, tubal ligation), orals, injectables, 2 forms of barrier methods (eg, diaphragm), intrauterine devices (IUDs), and hormonal therapy.

⁃ Eastern cooperative oncology group (ECOG) performance status of ≤ 1.

⁃ Major surgery must be completed and recovered at least 4 weeks prior to the first dose of study treatment.

⁃ Participants must meet the following organ and marrow function as defined below:

∙ Absolute neutrophil count ≥ 1,000/mm3

‣ Platelets ≥ 100,000/mm3

‣ AST(SGOT)/ALT(SGPT) ≤ 3 × institutional ULN

‣ Total bilirubin ≤1.5 × institutional upper limit of normal (ULN) (except Gilbert's or disease-related hemolysis, then \< 3 × ULN)

‣ Albumin ≥ 3.0 g/dL

‣ Serum creatinine ≤ 2.0 mg/dL OR creatinine clearance ≥ 40 mL/min/1.73 m2 by Cockcroft-Gault Formula (Appendix C.1)

‣ Oxygen saturation: ≥ 90% on room air

⁃ Participants with a prior malignancy whose natural history or treatment does not have the potential to interfere with the safety or efficacy assessment of the investigational regimen are eligible for this trial.

⁃ Known history or current symptoms of cardiac disease, or history of treatment with cardiotoxic agents, should have a clinical risk assessment of cardiac function using the New York Heart Association (NYHA) Functional Classification (Appendix B.2). To be eligible for this trial, participants should be class 2B or better.

⁃ Expected survival \> 16 weeks.

⁃ Stated willingness to comply with study procedures.

⁃ Able to attend required study visits and return for adequate follow-up, as required by this protocol.

• All inclusion criteria must be answered yes for a participant to participate in the trial.